Upstream Bio (UPB) Q2 R&D Soars 169%
Upstream Bio (NASDAQ:UPB), a biotechnology company developing new therapies for respiratory diseases, released its second quarter 2025 results on August 6, 2025. The main headline was rapid advancement in clinical trials for its lead drug candidate, verekitug, with major enrollment milestones hit in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Revenue (GAAP) was $0.9 million for Q2 2025, above the $0.69 million estimate. Year on year, the company’s investment in research and development (GAAP) increased significantly, reflecting its push toward critical Phase 2 trial results. Overall, the quarter was marked by clinical progress and increased spending, with ample cash reserves highlighted as a buffer for future operations.
Source: Analyst estimates for the quarter provided by FactSet.
Upstream Bio is focused on treating respiratory diseases with significant medical needs. Its lead asset, verekitug, is a monoclonal antibody designed to target and block the thymic stromal lymphopoietin (TSLP) receptor. This drug aims to address severe asthma, chronic obstructive pulmonary disease (COPD), and CRSwNP.
Source Fool.com
